|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.303 SEK | -0.33% |
|
-5.02% | -65.57% |
| 06-14 | Biosergen AB Approves Board Changes | CI |
| 06-11 | Biosergen AB Receives the Final Permission Required to Test Lead Candidate BSG005 in Patients with Invasive Fungal Infection | CI |
Biosergen AB reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was SEK 0.693 million compared to SEK 5.32 million a year ago. Net loss was SEK 6.89 million compared to SEK 5.03 million a year ago.
Basic loss per share from continuing operations was SEK 0.05 compared to SEK 0.18 a year ago. Diluted loss per share from continuing operations was SEK 0.05 compared to SEK 0.18 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -65.57% | 4.11M | |
| +16.49% | 122B | |
| +21.73% | 116B | |
| +22.18% | 27.03B | |
| -21.81% | 20.36B | |
| -16.89% | 16.43B | |
| -18.81% | 15.91B | |
| -44.74% | 15.6B | |
| +62.72% | 14.94B | |
| +3.09% | 13.59B |
BIOSERGEN AB 
